Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and Pembrolizumab in Metastatic Colorectal Cancer
NCT03657641Phase 2Active, not recruiting
- Sponsor
- University of Southern California
- Start
- Jun 2019
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, regorafenib in colorectal cancer (CRC), sponsored by University of Southern California. Started Jun 2019; status: active, not recruiting.
02
Drugs
pembrolizumabregorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03657641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657641.